FDMT4D Molecular Therapeutics, Inc.
$12.69+53% 1Y
$12.69
$7.1952 weeks$16.74
FDMT in its own filings
Nothing in FDMT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
112
Events found in the filings · across 438 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 28, 2026
Most recent filing · Form 8-K
- Record starts
- Nov 17, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity17 occurrences
- 2026-05-11
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”)Other event · Form 8-K
- Aug 13, 20264DMT Reports Second Quarter 2026 Financial Results, Operational Highlights.Earnings release · press release
- Jun 29, 2026On June 24, 2026 (the “Closing Date”), 4D Molecular Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), providing for term loans in an aggregate principal amount of up to $200.0 million, subject to the terms and conditions set forth …Material agreement entered · Form 8-K
- May 7, 20264DMT Reports First Quarter 2026 Financial Results, Operational Highlights.Earnings release · press release
- Mar 30, 2026On March 25, 2026, the Board of Directors of 4D Molecular Therapeutics, Inc. (the “Company”) appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately.Director or officer change · Form 8-K
- Mar 18, 20264DMT Reports Full Year 2025 Financial Results, Operational Highlights.Earnings release · press release
- Jan 26, 2026Issuance of Pre-Funded Warrants in Exchange for Common Stock On January 22, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) entered into exchange agreements with RA Capital Healthcare Fund, L.P. (“RA Capital”) and Biotechnology Value Fund, L.P. and its affiliates (“BVF”), pursuant to which RA Capital exchanged …Unregistered sale of equity · Form 8-K
- Jan 7, 2026Departure of President and Chief Operating Officer On December 31, 2025, in connection with his transition to a new part-time employment position, Fariborz Kamal, Ph.D., resigned as President and Chief Operating Officer of the Company effective immediately to pursue other opportunities.Earnings release · Form 8-K
- Dec 10, 2025On December 10, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) announced its intention to implement protocol amendments (the “Amendments”) to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD (the “4FRONT Trials”) to increase target enrollment from 400 to 480 patients per trial.Other event · Form 8-K
- Nov 17, 2025On November 17, 2025, Kristian Humer joined 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Financial Officer and Principal Financial Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…